Veritas In Silico (TSE:130A) ROCE % : -0.29% (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Veritas In Silico ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Veritas In Silico's annualized ROCE % for the quarter that ended in Jun. 2024 was -0.29%.

Veritas In Silico ROCE % Historical Data

The historical data trend for Veritas In Silico's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veritas In Silico ROCE % Chart

Veritas In Silico Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-13.99

-8.59

2.41

Veritas In Silico Quarterly Data
	Dec21	Dec22	Sep23	Dec23	Mar24	Jun24
ROCE %	Get a 7-Day Free Trial			-	-	-0.52	-13.22	-0.29

Veritas In Silico ROCE % Calculation

Veritas In Silico's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	37.623	/	( ( (1598.576 - 55.986)	+	(1655.531 - 79.892) )	/ 2 )
	=	37.623	/	( (1542.59	+	1575.639)	/ 2 )
	=	37.623	/	1559.1145
	=	2.41 %

Veritas In Silico's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Mar. 2024 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Mar. 2024 )		(Q: Jun. 2024 )
	=	-6.832	/	( ( (2416.24 - 58.051)	+	(2393.107 - 37.271) )	/ 2 )
	=	-6.832	/	( ( 2358.189	+	2355.836 )	/ 2 )
	=	-6.832	/	2357.0125
	=	-0.29 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

Veritas In Silico (TSE:130A) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Veritas In Silico ROCE % Related Terms

Thank you for viewing the detailed overview of Veritas In Silico's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Veritas In Silico Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veritas In Silico Inc (TSE:130A) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1-11-1, Nishigotanda, Shinagawa-ku, Tokyo, JPN, 141-0031

Website

https://www.veritasinsilico.com

Veritas In Silico Inc is engaged in discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. It has ibVIS platform that combines informatics (i) and experimental biology at Veritas In Silico (VIS) that will bring to fruition mRNA-targeted drugs.

Veritas In Silico Headlines

No Headlines